Updated:
Eagle Pharmaceuticals
Michael Graves leads Eagle Pharmaceuticals (NASDAQ: EGRX), a specialty firm focused on injectable oncology and critical care drugs like PEMFEXY and...
Eagle Pharmaceuticals
Eagle Pharmaceuticals operates as a fully diversified specialty pharmaceutical company, publicly trading under the ticker EGRX. CEO Michael Graves guides a commercial portfolio focused on injectable treatments for critical care and oncology patients. The company maintains corporate headquarters in Woodcliff Lake, New Jersey, supplementing its drug development efforts with a research center in Cambridge, Massachusetts and a regional office in Indianapolis. The firm's development strategy centers on acquiring and optimizing injectable drugs for hospital and acute-care settings. Its commercial products include PEMFEXY (pemetrexed injection), BELRAPZO and BENDEKA (bendamustine HCl injection), RYANODEX (dantrolene sodium for injectable suspension), BYFAVO (remimazolam for injection), and BARHEMSYS (amisulpride injection). Eagle identifies itself as having a pipeline of new chemical entities (NCEs) for oncology and critical care, describing first-in-class potential. The firm's collaboration with Teva Pharmaceuticals for products like BENDEKA shows its use of distribution partnerships to reach clinical markets in North America. Since 2023, the company has actively restructured its asset base. Its most recent strategic maneuver was the announced divestiture of Barhemsys, signaling a focus on narrower portfolio priorities. Eagle does not publicly disclose aggregate capital invested into its pipeline or acquisitions. The senior leadership team includes CEO Michael Graves, CFO Christopher Krawtschuk, and Chief Strategy Officer Daniel O'Connor, while an independent board featuring members like medical doctor Luciana Borio provides clinical oversight. Eagle blends the regulatory requirements of a public company with a small-biotech development model. Unlike a conventional private investment firm allocating capital to outside ventures, Eagle uses its balance sheet to buy commercial-stage drugs and advance its own NCE candidates. This operational posture — acquiring approved therapies and pushing them through hospital pharmacy channels — creates a distinct financial profile where revenue cycles on formulary adoption and patent cliffs, not fund structures.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Woodcliff Lake
Corporate office
Woodcliff Lake, NJ, United States
Additional offices
Cambridge, MA · Indianapolis, IN
Principals
Michael Graves
Chief Executive Officer & Chairman of the Board
Christopher Krawtschuk
Chief Financial Officer
Daniel O'Connor
Chief Strategy Officer, Head of Corporate Development
Sector focus
Frequently asked questions
Is Eagle Pharmaceuticals a private investment fund or an operating company?
Eagle Pharmaceuticals is a publicly traded operating company, not a private investment fund. It is listed on NASDAQ under ticker EGRX and is structured as a specialty pharmaceutical company. The firm discovers, develops, and markets its own branded and generic injectable products directly to healthcare systems, rather than investing capital in external ventures.
What is Eagle's expertise within the pharmaceutical sector?
The firm concentrates on injectable treatments for critical care and oncology in hospital settings. Its portfolio contains both complex generic injectables and new chemical entities (NCEs). Marketing names such as BYFAVO for procedural sedation and PEMFEXY for oncology reflect a focus on faster or safer administration in acute-care environments.
Does Eagle Pharmaceuticals operate international subsidiaries or partnerships?
The firm's disclosed physical operations are all within the United States, with offices in New Jersey, Massachusetts, and Indiana. Its public materials cite a collaboration with Teva Pharmaceuticals on a bendamustine injection, but the geographical scope of that partnership is not detailed beyond North American distribution as shown on official packaging.
Who runs investment decisions at Eagle Pharmaceuticals?
Business development and pipeline strategy are led by CEO Michael Graves and Chief Strategy Officer Daniel O'Connor, who also serves as Head of Corporate Development. Because Eagle is an operating company, investment decisions — such as acquiring or divesting a drug — are made by this leadership team and approved by a board of directors that includes medical scientist Luciana Borio.
What investment stages does Eagle Pharmaceuticals typically target?
Eagle does not invest in startups or venture-stage biotech. The company targets already approved or late-stage development assets that it can commercialize through optimized formulations for hospital use. Its product roster suggests a preference for acquiring mature, commercially available injectable drugs rather than funding preclinical discovery.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: